@article{88176,
  keywords = {Animals, Humans, Disease Models, Animal, Translational Medical Research, Urinary Bladder Neoplasms, Xenograft Model Antitumor Assays},
  author = {David DeGraff and Victoria Robinson and Jay Shah and William Brandt and Guru Sonpavde and Yibin Kang and Monica Liebert and Xue-Ru Wu and John Taylor and Translational Science Working Group of the Bladder Advocacy Network Think Tank},
  title = {Current preclinical models for the advancement of translational bladder cancer research.},
  abstract = {<p>Bladder cancer is a common disease representing the fifth most diagnosed solid tumor in the United States. Despite this, advances in our understanding of the molecular etiology and treatment of bladder cancer have been relatively lacking. This is especially apparent when recent advances in other cancers, such as breast and prostate, are taken into consideration. The field of bladder cancer research is ready and poised for a series of paradigm-shifting discoveries that will greatly impact the way this disease is clinically managed. Future preclinical discoveries with translational potential will require investigators to take full advantage of recent advances in molecular and animal modeling methodologies. We present an overview of current preclinical models and their potential roles in advancing our understanding of this deadly disease and for advancing care.</p>
},
  year = {2013},
  journal = {Mol Cancer Ther},
  volume = {12},
  pages = {121-30},
  month = {02/2013},
  issn = {1538-8514},
  doi = {10.1158/1535-7163.MCT-12-0508},
  language = {eng},
}